NCT04283539View on ClinicalTrials.gov

Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

RecruitingOBSERVATIONAL
Enrollment

238

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

February 28, 2025

Conditions
Cancer
Interventions
DRUG

systemic corticosteroid or biologic

Treatment with systemic corticosteroids or biologic therapies (for corticosteroid refractory patients or these in which corticosteroids are not the treatment of choice)

Trial Locations (3)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

80206

RECRUITING

National Jewish Health, Denver

RECRUITING

The Melanoma and Skin Cancer Institute, Denver

All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

National Jewish Health

OTHER

NCT04283539 - Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy | Biotech Hunter | Biotech Hunter